IsoRay (ISR) Posts Earnings Results, Hits Expectations

IsoRay (NYSEAMERICAN:ISR) posted its quarterly earnings data on Thursday. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02), Morningstar.com reports. The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million.

IsoRay stock opened at $0.44 on Friday. IsoRay has a twelve month low of $0.27 and a twelve month high of $1.22.

A number of analysts have recently issued reports on the stock. HC Wainwright set a $1.00 price objective on shares of IsoRay and gave the stock a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research downgraded shares of IsoRay from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th.

A number of institutional investors have recently bought and sold shares of the business. Highland Private Wealth Management bought a new stake in IsoRay in the fourth quarter worth $39,000. Vanguard Group Inc increased its position in shares of IsoRay by 24.7% in the third quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after acquiring an additional 367,324 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of IsoRay by 24.7% in the third quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after acquiring an additional 367,324 shares during the period.

COPYRIGHT VIOLATION NOTICE: This news story was posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.wkrb13.com/2019/05/11/isoray-isr-posts-earnings-results-hits-expectations.html.

About IsoRay

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Further Reading: Real Estate Investment Trust (REIT) ETF

Earnings History for IsoRay (NYSEAMERICAN:ISR)

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.